Radioimmunoguided Surgery for Colorectal Cancer - An Overview
Many different monoclonal antibodies used experimentally and clinically are highly tumour-specific. Radiolahelling of these antibodies has been successfully accomplished. lmmunoscintigraphy of primary and metastatic cancers has a reported sensitivity of 59 to 70%. However, in many studies, operative...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
1990-01-01
|
| Series: | Canadian Journal of Gastroenterology |
| Online Access: | http://dx.doi.org/10.1155/1990/420697 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850214373906186240 |
|---|---|
| author | Wojciech Brzezinski Olin G Thurston Ernest Wiens |
| author_facet | Wojciech Brzezinski Olin G Thurston Ernest Wiens |
| author_sort | Wojciech Brzezinski |
| collection | DOAJ |
| description | Many different monoclonal antibodies used experimentally and
clinically are highly tumour-specific. Radiolahelling of these antibodies has been
successfully accomplished. lmmunoscintigraphy of primary and metastatic cancers
has a reported sensitivity of 59 to 70%. However, in many studies, operative
and histologic confirmation is lacking. Radioimmunoguided surgery is a promising
new adjunctive technique for the surgical treatment of colorectal cancer. Its
reported sensitivity ranges between 70 and 100% and specificity between 66 and
100%. In approximately one-third of patients wirh colorectal cancer, additional
intraoperative information concerning the presence of subclinical tumours was
gained using radioimmunoguided surgery. This system has the potential to assist
the surgeon in performing complete resection of cancer and decrease the local
recurrence rate. This could be of particular clinical importance for rectosigmoid
tumours where the reported local recurrence rate is as high as 30%. Despite the
advances made, many problems still need to be resolved. The important ones
include: finding an antibody with high tumour specificity and at the same time
rapid clearance from the blood pool and normal tissue - this would avoid the
delay between monoclonal antibody injection and surgery and would make this
approach more easily accepted by the patient; and use of alternative isotopes for
radiolabelling. Radioimmunoguided surgery has the potential to change the way
surgery for colorectal cancer is being performed. It offers the possibility of
improvement in patient survival. |
| format | Article |
| id | doaj-art-85c310c350d049e5b162dfd9bb0bcebf |
| institution | OA Journals |
| issn | 0835-7900 |
| language | English |
| publishDate | 1990-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Canadian Journal of Gastroenterology |
| spelling | doaj-art-85c310c350d049e5b162dfd9bb0bcebf2025-08-20T02:08:56ZengWileyCanadian Journal of Gastroenterology0835-79001990-01-014521521810.1155/1990/420697Radioimmunoguided Surgery for Colorectal Cancer - An OverviewWojciech BrzezinskiOlin G ThurstonErnest WiensMany different monoclonal antibodies used experimentally and clinically are highly tumour-specific. Radiolahelling of these antibodies has been successfully accomplished. lmmunoscintigraphy of primary and metastatic cancers has a reported sensitivity of 59 to 70%. However, in many studies, operative and histologic confirmation is lacking. Radioimmunoguided surgery is a promising new adjunctive technique for the surgical treatment of colorectal cancer. Its reported sensitivity ranges between 70 and 100% and specificity between 66 and 100%. In approximately one-third of patients wirh colorectal cancer, additional intraoperative information concerning the presence of subclinical tumours was gained using radioimmunoguided surgery. This system has the potential to assist the surgeon in performing complete resection of cancer and decrease the local recurrence rate. This could be of particular clinical importance for rectosigmoid tumours where the reported local recurrence rate is as high as 30%. Despite the advances made, many problems still need to be resolved. The important ones include: finding an antibody with high tumour specificity and at the same time rapid clearance from the blood pool and normal tissue - this would avoid the delay between monoclonal antibody injection and surgery and would make this approach more easily accepted by the patient; and use of alternative isotopes for radiolabelling. Radioimmunoguided surgery has the potential to change the way surgery for colorectal cancer is being performed. It offers the possibility of improvement in patient survival.http://dx.doi.org/10.1155/1990/420697 |
| spellingShingle | Wojciech Brzezinski Olin G Thurston Ernest Wiens Radioimmunoguided Surgery for Colorectal Cancer - An Overview Canadian Journal of Gastroenterology |
| title | Radioimmunoguided Surgery for Colorectal Cancer - An Overview |
| title_full | Radioimmunoguided Surgery for Colorectal Cancer - An Overview |
| title_fullStr | Radioimmunoguided Surgery for Colorectal Cancer - An Overview |
| title_full_unstemmed | Radioimmunoguided Surgery for Colorectal Cancer - An Overview |
| title_short | Radioimmunoguided Surgery for Colorectal Cancer - An Overview |
| title_sort | radioimmunoguided surgery for colorectal cancer an overview |
| url | http://dx.doi.org/10.1155/1990/420697 |
| work_keys_str_mv | AT wojciechbrzezinski radioimmunoguidedsurgeryforcolorectalcanceranoverview AT olingthurston radioimmunoguidedsurgeryforcolorectalcanceranoverview AT ernestwiens radioimmunoguidedsurgeryforcolorectalcanceranoverview |